FDA Commissioner Confirmed Amid Pharmaceutical Industry Ties Controversy

| Importance: 8/10 | Status: confirmed

Dr. Robert Califf confirmed as FDA Commissioner by a narrow Senate vote of 50-46, highlighting ongoing concerns about pharmaceutical industry regulatory capture. Historical evidence suggests a systemic ‘revolving door’ between FDA and pharmaceutical companies, with approximately 27% of drug reviewers transitioning to industry roles. This pattern creates significant potential conflicts of interest and undermines regulatory oversight capabilities.

Key Actors

Robert Califf Senate FDA Leadership Pharmaceutical Industry Executives

Tags

regulatory-capture revolving-door pharmaceutical-industry conflict-of-interest senate-confirmation

Sources (3)

Help Improve This Timeline

Found an error or have additional information? You can help improve this event.

✏️ Edit This Event ➕ Suggest New Event

Edit: Opens GitHub editor to submit corrections or improvements via pull request.
Suggest: Opens a GitHub issue to propose a new event for the timeline.